Galderma Group AGXSWX:GALD -0.89%15 Return-on-Tangible-Asset is 25.07% as of Dec. 2025, which is 172% above its 10-year median of 9.23. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Galderma Group AG ranks better than 93.73% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Galderma Group AG's annualizedNet Income for the quarter that ended in Dec. 2025 was CHF668 Mil. Galderma Group AG's average total tangible assets for the quarter that ended in Dec. 2025 was CHF2,663 Mil. Therefore, Galderma Group AG's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 25.07%.
The historical rank and industry rank for Galderma Group AG's Return-on-Tangible-Asset or its related term are showing as below:
XSWX:GALD'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2.36 Med: 9.23 Max: 19.16
Current: 19.16
During the past 5 years, Galderma Group AG's highest Return-on-Tangible-Asset was 19.16%. The lowest was -2.36%. And the median was 9.23%.
XSWX:GALD's Return-on-Tangible-Asset is ranked better than 93.73% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.17
vs XSWX:GALD: 19.16
Galderma Group AG (XSWX:GALD) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Galderma Group AG Return-on-Tangible-Asset Related Terms
Galderma Group AG Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 25.07% mean?
Galderma Group AG (XSWX:GALD) has a Return-on-Tangible-Asset of 25.07% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Galderma Group AG and its competitors. This is 172% above median its historical median of 9.23. According to the industry distribution chart, Galderma Group AG ranks #63 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 6.3%.
Is Galderma Group AG's Return-on-Tangible-Asset too high?
Galderma Group AG's current Return-on-Tangible-Asset of 25.07% is 172% above median its 10-year median of 9.23. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.17. Galderma Group AG's value of 25.07% is 690.9% above this industry median. Based on the distribution chart, Galderma Group AG ranks #63 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #63 out of 1005 companies for Return-on-Tangible-Asset. This places Galderma Group AG in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.17. Galderma Group AG's value of 25.07% is 690.9% above this benchmark. While the company's 10-year median is 9.23 vs. the industry median of 3.17, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.17, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current Return-on-Tangible-Asset of 25.07% is 690.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current Return-on-Tangible-Asset is 25.07%, which is 172% above median its own 10-year median of 9.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Return-on-Tangible-Asset of 25.07%. The current Return-on-Tangible-Asset is 25.07%, which is 172% above median its 10-year median of 9.23 and 690.9% above the Drug Manufacturers industry median of 3.17. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Return-on-Tangible-Asset is 25.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 